NCT05846724 2026-01-22
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT06068153 2024-11-20
AMBER
ETOP IBCSG Partners Foundation
Phase 2 Withdrawn
NCT03801499 2020-05-21
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Withdrawn
NCT03919383 2019-06-03
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03775707 2019-05-06
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 2 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03746249 2019-04-17
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT02846766 2018-08-02
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
University of California, San Diego
Phase 2 Withdrawn
NCT03005015 2016-12-29
Lenvatinib in Second Line Endometrial Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn